Meeting
2011 ASCO Annual Meeting
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC).
Authors
V. Papadimitrakopoulou
University of Texas M. D. Anderson Cancer Center, Houston, TX
V. Papadimitrakopoulou , J. Heymach , S. J. Frank , J. Myers , H. Lin , H. T. Tran , C. Chen , F. R. Hirsch , P. B. Langmuir , J. R. Vasselli , S. M. Lippman , D. Raben
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00450138
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5510)
Abstract #
5510
Poster Bd #
4
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I dose escalation of stereotactic body radiation therapy and concurrent cisplatin for re-irradiation of unresectable, recurrent head and neck squamous cell carcinoma.
First Author: Michelle Echevarria
Poster
2017 ASCO Annual Meeting
Phase I study of the anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
First Author: Julie E. Bauman
Poster
2023 ASCO Annual Meeting
A phase 1 study of concurrent cabozantinib and cetuximab in recurrent or metastatic head and neck squamous cell cancer.
First Author: Antoine Desilets
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau